Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels

被引:63
|
作者
Kathiresan, S
Gabriel, SB
Yang, Q
Lochner, AL
Larson, MG
Levy, D
Tofler, GH
Hirschhorn, JN
O'Donnell, CJ
机构
[1] NHLBI, Framingham Heart Dis Epidemiol Study, Framingham, MA 01702 USA
[2] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA
[3] MIT, Cambridge, MA 02139 USA
[4] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA
[5] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02215 USA
[6] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[7] Royal N Shore Hosp, Sydney, NSW, Australia
[8] Harvard Univ, Sch Med, Childrens Hosp, Div Genet, Boston, MA 02115 USA
[9] Harvard Univ, Sch Med, Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA
[10] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA
[11] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02115 USA
关键词
plasminogen; epidemiology; genetics; genomics; fibrinolysis;
D O I
10.1161/CIRCULATIONAHA.105.547836
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Using a linkage disequilibrium (LD) - based approach, we sought to comprehensively define common genetic variation at the plasminogen activator inhibitor-1 ( PAI-1) locus and relate common single nucleotide polymorphisms ( SNPs) and haplotypes to plasma PAI-1 levels. Methods and Results - In reference pedigrees, we defined LD structure across a 50-kb genomic segment spanning the PAI-1 locus via a dense SNP map ( 1 SNP every 2 kb). Eighteen sequence variants that capture underlying common genetic variation were genotyped in 1328 unrelated Framingham Heart Study participants who had plasma PAI-1 antigen levels measured. Regression analyses were used to examine associations of individual SNPs and of inferred haplotypes with multivariable-adjusted PAI-1 levels. Two genetic variants, SNP rs2227631 and the 4G/5G polymorphism, were strongly associated ( P < 0.0001) with PAI-1 levels. SNP rs2227631 is in tight LD ( D' = 0.97, r(2) = 0.78) with the 4G/5G polymorphism, which makes it difficult to distinguish which of these 2 polymorphisms is responsible for the association with PAI-1 levels. In stepwise analysis considering all polymorphisms tested, 3 SNPs, rs2227631 ( or the correlated 4G/5G polymorphism), rs6465787,and rs2227674, each explained 2.5%, 1%, and 1%, respectively, of the residual variance in multivariable-adjusted PAI-1 levels ( stepwise P < 0.0001, P = 0.04, and P = 0.03, respectively). A single common haplotype, at 50% frequency among Framingham Heart Study participants, was strongly associated with higher PAI-1 levels ( haplotype-specific P = 0.00001). The susceptibility haplotype harbors the minor alleles of SNP rs2227631 and the 4G/5G polymorphism. Conclusions - Three sequence variants at the PAI-1 locus, in sum, explain approximate to 5% of the residual variance in multivariable-adjusted PAI-1 levels. For quantitative cardiovascular traits such as circulating biomarkers, defining LD structure in a candidate gene followed by association analyses with both SNPs and haplotypes is an effective approach to localize common susceptibility alleles.
引用
收藏
页码:1728 / 1735
页数:8
相关论文
共 50 条
  • [1] Gene-based Haplotypes at the plasminogen activator inhibitor-1 locus are associated with circulating plasminogen activator inhibitor-1 levels.
    Kathiresan, S
    Yang, Q
    Lochner, A
    Larson, MG
    Tofler, GH
    Gabriel, S
    O'Donnell, CJ
    [J]. CIRCULATION, 2004, 109 (07) : E77 - E77
  • [2] GENETIC-VARIATION AT THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 LOCUS IS ASSOCIATED WITH ALTERED LEVELS OF PLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 ACTIVITY
    DAWSON, S
    HAMSTEN, A
    WIMAN, B
    HENNEY, A
    HUMPHRIES, S
    [J]. ARTERIOSCLEROSIS AND THROMBOSIS, 1991, 11 (01): : 183 - 190
  • [3] Plasminogen activator inhibitor-1
    Gils, A
    Declerck, PJ
    [J]. CURRENT MEDICINAL CHEMISTRY, 2004, 11 (17) : 2323 - 2334
  • [4] Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke
    Johansson, L
    Jansson, JH
    Boman, K
    Nilsson, TK
    Stegmayr, B
    Hallmans, G
    [J]. STROKE, 2000, 31 (01) : 26 - 32
  • [5] Polymerization of plasminogen activator inhibitor-1
    Zhou, A
    Faint, R
    Charlton, P
    Dafforn, TR
    Carrell, RW
    Lomas, DA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (12) : 9115 - 9122
  • [6] Plasminogen Activator Inhibitor-1 in Aging
    Yamamoto, Koji
    Takeshita, Kyosuke
    Saito, Hidehiko
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2014, 40 (06): : 652 - 659
  • [7] Plasminogen activator inhibitor-1 and the kidney
    Eddy, AA
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2002, 283 (02) : F209 - F220
  • [8] PLASMINOGEN-ACTIVATOR INHIBITOR-1
    LOSKUTOFF, DJ
    MIMURO, J
    HEKMAN, C
    [J]. THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 534 - 534
  • [9] Plasminogen activator inhibitor-1 and Restenosis
    Garg, Nadish
    Fay, William P.
    [J]. CURRENT DRUG TARGETS, 2007, 8 (09) : 1003 - 1006
  • [10] GENETIC-VARIATION AT THE PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) LOCUS
    DAWSON, S
    HAMSTEN, A
    WIMAN, B
    HENNEY, A
    HUMPHRIES, S
    [J]. FIBRINOLYSIS, 1990, 4 : 51 - 53